Likenchat

created a new article

25 w

Better With Age Clothing | Premium Jeans, Shirts & Shorts | #better With Age

Better With Age Clothing | Premium Jeans, Shirts & Shorts

Discover Better With Age clothing, including premium jeans, stylish shirts, and comfortable shorts designed for timeless streetwear, durability, and everyday comfort.

Comment

created a new article

25 w

Accounting and Advisory Services for UAE Market | #fmc

Accounting and Advisory Services for UAE Market

By integrating services such as corporate tax, internal audit, fractional CFO support, and AI-driven accounting, businesses in the UAE can build a strong financial foundation and stay ahead in a competitive market.

Comment

"Pharmaqo is a dedicated platform for individuals seeking high-quality performance and wellness solutions. We specialize in providing a range of advanced compounds, including injectables, SARMs, HGH, and oral products, carefully selected to meet the demands of serious athletes and performance-driven individuals. Our focus is on consistency, quality, and reliability, ensuring that every product meets high standards. official website
https://pharmaqo.fit/

Comment

25 w

Chronic Pulmonary Hypertension Treatment Market to Reach US$ 12.3 Billion by 2033, Exhibiting 6.7% CAGR
Evolving clinical protocols and targeted therapies are reshaping the chronic pulmonary hypertension treatment landscape, creating new avenues for patient care and market expansion.
Global **Chronic Pulmonary Hypertension Treatment Market Overview
The chronic pulmonary hypertension treatment market is currently positioned as a critical segment within the global cardiovascular therapeutics sector, valued at US$ 7.8 billion in 2026. The market’s trajectory is defined by rising disease prevalence, increased clinical awareness, and the integration of advanced pharmacological therapies. Key demand drivers include the growing geriatric population, a higher incidence of comorbidities, and improved diagnostic capabilities, which collectively contribute to earlier disease identification and intervention.
From 2026 to 2033, the market is projected to expand at a 6.7% CAGR, reaching US$ 12.3 billion. This growth is underpinned by regulatory support for novel drug approvals, adoption of combination therapies, and the emergence of precision medicine approaches.